加拿大英属哥伦比亚大学Jason G. Andrade团队比较了冷冻消融或药物治疗心房颤动的预后。2020年11月16日，该研究发表在《新英格兰医学杂志》上。
Title: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation | NEJM
Author: Jason G. Andrade, M.D.,, George A. Wells, Ph.D.,, Marc W. Deyell, M.D.,, Matthew Bennett, M.D.,, Vidal Essebag, M.D., Ph.D.,, Jean Champagne, M.D.,, Jean-Francois Roux, M.D.,, Derek Yung, M.D.,, Allan Skanes, M.D.,, Yaariv Khaykin, M.D.,, Carlos Morillo, M.D.,, Umjeet Jolly, M.D.,, Paul Novak, M.D.,, Evan Lockwood, M.D.,, Guy Amit, M.D.,, Paul Angaran, M.D.,, John Sapp, M.D.,, Stephan Wardell, M.D.,, Sandra Lauck, Ph.D.,, Laurent Macle, M.D.,, and Atul Verma, M.D.
Guidelines recommend a trial of one or more antiarrhythmic drugs before catheter ablation is considered in patients with atrial fibrillation. However, first-line ablation may be more effective in maintaining sinus rhythm.
We randomly assigned 303 patients with symptomatic, paroxysmal, untreated atrial fibrillation to undergo catheter ablation with a cryothermy balloon or to receive antiarrhythmic drug therapy for initial rhythm control. All the patients received an implantable cardiac monitoring device to detect atrial tachyarrhythmia. The follow-up period was 12 months. The primary end point was the first documented recurrence of any atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) between 91 and 365 days after catheter ablation or the initiation of an antiarrhythmic drug. The secondary end points included freedom from symptomatic arrhythmia, the atrial fibrillation burden, and quality of life.
At 1 year, a recurrence of atrial tachyarrhythmia had occurred in 66 of 154 patients (42.9%) assigned to undergo ablation and in 101 of 149 patients (67.8%) assigned to receive antiarrhythmic drugs (hazard ratio, 0.48; 95% confidence interval [CI], 0.35 to 0.66; P<0.001). Symptomatic atrial tachyarrhythmia had recurred in 11.0% of the patients who underwent ablation and in 26.2% of those who received antiarrhythmic drugs (hazard ratio, 0.39; 95% CI, 0.22 to 0.68). The median percentage of time in atrial fibrillation was 0% (interquartile range, 0 to 0.08) with ablation and 0.13% (interquartile range, 0 to 1.60) with antiarrhythmic drugs. Serious adverse events occurred in 5 patients (3.2%) who underwent ablation and in 6 patients (4.0%) who received antiarrhythmic drugs.
Among patients receiving initial treatment for symptomatic, paroxysmal atrial fibrillation, there was a significantly lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation than with antiarrhythmic drug therapy, as assessed by continuous cardiac rhythm monitoring.